{
    "paper_id": "3e9cebd42a3e367e58c6cd2472175ddf22f14ae4",
    "metadata": {
        "title": "Journal Pre-proof Distinct immunological signatures discriminate severe COVID-19 from non-SARS- CoV-2-driven critical pneumonia",
        "authors": [
            {
                "first": "Stefanie",
                "middle": [],
                "last": "Kreutmair",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Susanne",
                "middle": [],
                "last": "Unger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Nicol\u00e1s",
                "middle": [],
                "last": "Gonzalo N\u00fa\u00f1ez",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Florian",
                "middle": [],
                "last": "Ingelfinger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Chiara",
                "middle": [],
                "last": "Alberti",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Donatella",
                "middle": [],
                "last": "De Feo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sinduya",
                "middle": [],
                "last": "Krishnarajah",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Manuel",
                "middle": [],
                "last": "Kauffmann",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ekaterina",
                "middle": [],
                "last": "Friebel",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sepideh",
                "middle": [],
                "last": "Babaei",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Benjamin",
                "middle": [],
                "last": "Gaborit",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Mirjam",
                "middle": [],
                "last": "Lutz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Nicole",
                "middle": [
                    "Puertas"
                ],
                "last": "Jurado",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Nisar",
                "middle": [
                    "P"
                ],
                "last": "Malek",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Siri",
                "middle": [],
                "last": "Goepel",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Peter",
                "middle": [],
                "last": "Rosenberger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Helene",
                "middle": [
                    "A"
                ],
                "last": "H\u00e4berle",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Ikram",
                "middle": [],
                "last": "Ayoub",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Sally",
                "middle": [],
                "last": "Al-Hajj",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Jakob",
                "middle": [],
                "last": "Nilsson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Manfred",
                "middle": [],
                "last": "Classen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Roland",
                "middle": [],
                "last": "Liblau",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Guillaume",
                "middle": [],
                "last": "Martin-Blondel",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Michael",
                "middle": [],
                "last": "Bitzer",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Antoine",
                "middle": [],
                "last": "Roquilly",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Burkhard",
                "middle": [],
                "last": "Becher",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Unger",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "N\u00fa\u00f1ez",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "N",
                "middle": [
                    "G"
                ],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "F",
                "middle": [],
                "last": "Alberti",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "C",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "De",
                "middle": [],
                "last": "Feo",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "D",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Kauffmann",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "M",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "E",
                "middle": [],
                "last": "Babaei",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Gaborit",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "B",
                "middle": [],
                "last": "Lutz",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "M",
                "middle": [],
                "last": "Jurado",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "N",
                "middle": [
                    "P"
                ],
                "last": "Malek",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "N",
                "middle": [
                    "P"
                ],
                "last": "Goepel",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "H",
                "middle": [
                    "A"
                ],
                "last": "Ayoub",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "I",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Al-Hajj",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "S",
                "middle": [],
                "last": "Nilsson",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "J",
                "middle": [],
                "last": "Classen",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "M",
                "middle": [],
                "last": "Liblau",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "R",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "Martin-Blondel",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "G",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "M",
                "middle": [],
                "last": "Roquilly",
                "suffix": "",
                "affiliation": {},
                "email": ""
            },
            {
                "first": "A",
                "middle": [],
                "last": "",
                "suffix": "",
                "affiliation": {},
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "). Compared to COVID-19m, the severe disease was 132 characterized by significantly lower frequencies of CD8 + T cells, coupled with higher 133 frequencies of B cells (Fig. S1D ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 167,
                    "end": 176,
                    "text": "(Fig. S1D",
                    "ref_id": null
                }
            ],
            "section": ""
        },
        {
            "text": "We next combined all cytometry parameters of the surface panel (Table S2A) (Fig. 1C, S1E) . Stratification of the COVID-19 cohort data by sex or age did not 141 reveal marked differences in immune phenotypes (Fig. S1F , S1G).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 63,
                    "end": 74,
                    "text": "(Table S2A)",
                    "ref_id": null
                },
                {
                    "start": 75,
                    "end": 89,
                    "text": "(Fig. 1C, S1E)",
                    "ref_id": null
                },
                {
                    "start": 208,
                    "end": 217,
                    "text": "(Fig. S1F",
                    "ref_id": null
                }
            ],
            "section": "134"
        },
        {
            "text": "To uncover the immunological dysregulation of COVID-19s that is distinct from the Table S3 ). Building on the 241 above-described common myeloid features, there were also phenotypic changes within this 242 compartment that were specific to COVID-19s. Specifically, there was significantly lower 243 expression of HLA-DR as well as the co-stimulatory ligand CD86 across antigen presenting 244 cell (APC) subsets, which persisted throughout the duration of our study and were not (Fig. 5B ). This NKT cell reduction was already apparent within the first week after can distinguish severe COVID-19 patients from mild disease with a sensitivity of 100% 264 already at day 0-2 after hospital admission. This finding defines NKT frequency as a 265 powerful predictive biomarker for COVID-19s evolution and furthermore suggesting a role of 266 these cells in the first phase of disease.",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 82,
                    "end": 90,
                    "text": "Table S3",
                    "ref_id": null
                },
                {
                    "start": 478,
                    "end": 486,
                    "text": "(Fig. 5B",
                    "ref_id": "FIGREF58"
                }
            ],
            "section": "142"
        },
        {
            "text": "In addition to the above-described upregulation of PD-1 predominantly in CD4 + T cells, 268 higher expression of PD-1 by CD4 + EM cells turned out to be a feature unique to 269 (ES vs HAP > 0.4), which positively correlated with severity grade (Fig. 5C, S5B ). ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 244,
                    "end": 257,
                    "text": "(Fig. 5C, S5B",
                    "ref_id": "FIGREF58"
                }
            ],
            "section": "267"
        },
        {
            "text": "The protein expression of CD38, another activation marker, across several T cell subsets 279 positively correlated with COVID-19 severity, with the highest significance (p < 0.0001, R 2 = 280 0.24) in CD4 -CD8 -(TCR\u03b3\u03b4 enriched) T cells (Fig. 5D, S5D ). Furthermore, we observed a ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 236,
                    "end": 249,
                    "text": "(Fig. 5D, S5D",
                    "ref_id": "FIGREF58"
                }
            ],
            "section": "278"
        },
        {
            "text": "Although failing to reach the stringent cut-off for being a unique COVID-19s specific feature 287 (ES vs HAP > 0.4), CD161 was also expressed at a significantly lower level on immature 288 and CD56 low CD16 + NK cells in the early phase of severe SARS-CoV-2 related illness 289 compared to mild disease (Fig. S5F) . Here, the kinetics of CD161 expression was low at the 290 beginning of disease with a delayed hyperreactivity in COVID-19s (Fig. S5F ). Further 291 dissecting the NK cell compartment, CD95 expression in the CD56 high NK subset positively 292 correlated with severity of COVID-19 and represents a unique characteristic specific to 293 SARS-CoV-2 infection (Fig. 5F, S5G) . As in the DC compartment described before, the 294 significant and specific reduction of this NK subset supports the Fas-mediated, activation-295 induced apoptosis as the mechanism underlying the shift from effector to immature NK cells 296 (Fig. S5H ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 303,
                    "end": 313,
                    "text": "(Fig. S5F)",
                    "ref_id": "FIGREF58"
                },
                {
                    "start": 439,
                    "end": 448,
                    "text": "(Fig. S5F",
                    "ref_id": "FIGREF58"
                },
                {
                    "start": 671,
                    "end": 685,
                    "text": "(Fig. 5F, S5G)",
                    "ref_id": "FIGREF58"
                },
                {
                    "start": 929,
                    "end": 938,
                    "text": "(Fig. S5H",
                    "ref_id": "FIGREF58"
                }
            ],
            "section": "286"
        },
        {
            "text": "Regarding the cytokine polarization profile, a reduced production of IFN-\u03b3 in CD4 + central 298 memory (CM) T cells was found to be COVID-19s specific and reflects the loss of CD4 + 299 J o u r n a l P r e -p r o o f 19s specific category and diverging from HAP recovered only partly, both in mild and severe compartment (Fig. 5I ).",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 321,
                    "end": 329,
                    "text": "(Fig. 5I",
                    "ref_id": "FIGREF58"
                }
            ],
            "section": "297"
        },
        {
            "text": "The recorded myeloid features in COVID-19s were even more pronounced in the HAP 304 patients (Fig. 4G, 4H ). In contrast, several identified COVID-19s specific T and NK cell 305 features were clearly different from what has been observed in HC and HAP (Fig. 5B , 5E, 306 5H, 5J). Taken together, whereas changes in the myeloid compartment are shared across 307 severe RS patients, our differential display approach extracted signatures of T cell Table S5 ). This predicted binding capacity for HLA-A,",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 93,
                    "end": 105,
                    "text": "(Fig. 4G, 4H",
                    "ref_id": null
                },
                {
                    "start": 252,
                    "end": 260,
                    "text": "(Fig. 5B",
                    "ref_id": "FIGREF58"
                },
                {
                    "start": 446,
                    "end": 454,
                    "text": "Table S5",
                    "ref_id": null
                }
            ],
            "section": "303"
        },
        {
            "text": "HLA-B and HLA-C was further called HLA score 50. Next, we integrated this dataset to our ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "331"
        },
        {
            "text": "In conclusion, we provide a translational path forward based on our differential immune map 357 specific for severe SARS-CoV-2 infection combined with predicted HLA class I binding 358 capacity to SARS-CoV-2 peptides, which can be used to guide therapeutic approaches (Table S2A) . After another washing step, the second 764 surface-antibody staining step (100 \u00b5l) was performed for 15 min at 4\u00b0C (Table S2A) ",
            "cite_spans": [],
            "ref_spans": [
                {
                    "start": 268,
                    "end": 279,
                    "text": "(Table S2A)",
                    "ref_id": null
                },
                {
                    "start": 397,
                    "end": 408,
                    "text": "(Table S2A)",
                    "ref_id": null
                }
            ],
            "section": "356"
        }
    ],
    "bib_entries": {
        "BIBREF2": {
            "ref_id": "b2",
            "title": "Early Transmission Dynamics in Wuhan, China",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "Y"
                    ],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Genomic characterisation and epidemiology of 2019 novel coronavirus: 991 implications for virus origins and receptor binding",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Zhao",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Niu",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Song",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Huang",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Zhu",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "565--574",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "GM-CSF blockade with 994 mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-995 centre, prospective cohort study",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Boffini",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Tentori",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Mette",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Farina",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet Rheumatol",
            "volume": "2",
            "issn": "",
            "pages": "465--473",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Longitudinal analyses reveal immunological misfiring 998 in severe COVID-19",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Oh",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "E"
                    ],
                    "last": "Israelow",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature",
            "volume": "584",
            "issn": "",
            "pages": "463--469",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Long covid could be four different syndromes, review suggests",
            "authors": [
                {
                    "first": "E",
                    "middle": [],
                    "last": "Mahase",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "BMJ",
            "volume": "1000",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "The end 1002 of gating? An introduction to automated analysis of high dimensional cytometry data",
            "authors": [
                {
                    "first": "F",
                    "middle": [],
                    "last": "Mair",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [
                        "J"
                    ],
                    "last": "Hartmann",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Mrdjen",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Tosevski",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Krieg",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Becher",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Eur J 1003 Immunol",
            "volume": "46",
            "issn": "",
            "pages": "34--43",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Deep immune profiling of 1006",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Kuri-Cervantes",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "B"
                    ],
                    "last": "Pampena",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "D&apos;andrea",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science (80-. 1007 )",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "369",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Estimating the size of treatment effects: moving 1009 beyond p values",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "J"
                    ],
                    "last": "Mcgough",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Faraone",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Psychiatry (Edgmont)",
            "volume": "6",
            "issn": "",
            "pages": "21--29",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "UMAP: Uniform Manifold 1011 Approximation and Projection",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Mcinnes",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Healy",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Saul",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Gro\u00dfberger",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "J. Open Source Softw",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "UMAP: Uniform Manifold Approximation and 1013 Projection",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Mcinnes",
                    "suffix": ""
                },
                {
                    "first": "N",
                    "middle": [],
                    "last": "Saul",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Gro\u00dfberger",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [
                        "J"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "JOSS",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Pathological inflammation in patients with COVID-19: a 1015 key role for monocytes and macrophages",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Merad",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "C"
                    ],
                    "last": "Martin",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nat. Rev. Immunol",
            "volume": "20",
            "issn": "",
            "pages": "355--362",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Cytokine release syndrome in severe COVID-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [
                        "B"
                    ],
                    "last": "Moore",
                    "suffix": ""
                },
                {
                    "first": "June",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [
                        "H"
                    ],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "CCR2 C COVID-19 severity COVID-19 severity COVID-19 severity COVID-19 severity COVID-19 severity Leukocytes (10^3/\u00b5l) Lymphocytes (10^3/\u00b5l) Monocytes",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Nakano",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Moran",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Nakano",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Whitehead",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Thomas",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Cook",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "Granulocytes (10^3/\u00b5l)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Leukocytes (10^3/\u00b5l) Lymphocytes (10^3/\u00b5l) Monocytes (10^3/\u00b5l)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Platelets (10^3/\u00b5l)",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": "",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF0": {
            "text": "Van Gassen et al., 2015) combined with UMAP dimensionality reduction (McInnes L Saul 128 N, Gro\u00dfberger L, 2018) (Fig. 1B, S1B, S1C). Comparison of PBMCs from HCs and COVID-129 19 patients revealed numerous frequency alterations of canonical immune subsets among 130 CD45 + cells, except CD4 + lymphocytes, NK cells and monocytes which were comparable 131 across all time points (TPs)",
            "latex": null,
            "type": "figure"
        },
        "FIGREF1": {
            "text": "to deeply 135 phenotype T cell, B cell, NK cell, DC and monocyte subsets from each cohort, assessing 136 their differentiation and activation state as well as their exhaustion profile. Following data 137 integration and HAP inclusion, a principal component analysis (PCA) of the resulting immune 138 landscapes showed a clear segregation of cells from HCs compared to both COVID-19 and 139 HAP groups, while COVID-19s patients shared signatures both with COVID-19m and HAP 140 patients",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "143 inflammatory, infectious immune signatures of HAP, we further enriched our dataset with an 144 overall lymphoid and myeloid cytokine profile of the different subpopulations (Tables S2B 145 and S2C). We introduced the statistical measure of the effect size (ES) to combine both 146 significance and fold change in one single statistical value, as proposed for clinical trials 147 before (McGough and Faraone, 2009; Sullivan and Feinn, 2012). We computed the ES of 148 the Mann-Whitney U test between the analyzed groups (Fig. 1D). Applying the interpretation 149 of ES by Cohen (0.1 -0.3 small effect, >0.3 intermediate and large effect) (Cohen, 1977), we 150 set the threshold for the comparison of mild versus severe COVID to 0.3. Due to the high 151 number of features reaching the threshold of 0.3 in the comparison COVID-19s versus HAP, 152 we applied a more stringent cut-off of 0.4 in order to exclusively filter COVID-19s-specific 153 features. This revealed that mild and severe COVID-19 exhibit distinct immune signatures 154 (represented by an ES > 0.3 and seen in the upper part of the dot plot in Fig. 1D), but in 155 addition, COVID-19s and HAP could be distinguished by a set of immune features 156 (displayed in the upper right square in Fig. 1D; threshold ES > 0.4 vs. HAP). Immune Taken together, COVID-19s presents immune features that are both shared and distinct 160 from other pneumonia and affect all immune compartments except for B cells. Shared T cell features between severe pathogen-induced RSs highlight the 162 emergence of hyperinflammatory and exhausted subsets in COVID-19s 163 Following selection of the common immunological trajectories shared across severe RS 164 patients (COVID-19s and HAP) (Fig. 1D, upper left square), we further extracted their 165 dynamic manifestation in the COVID-19 cohort by correlation to disease severity and 166 analysis over time. The identified patterns revealed predominantly the T cell compartment 167 (Fig. 2A, 2B, S2A, S2B,Table S3). The reduction in CD4 -CD8 -(TCR\u03b3\u03b4 enriched) T cell 168 frequency appeared to be progressive, reaching its lowest during the second week of 169 hospitalization (TP 3 (day 6-9)) (Fig. 2C). Moreover, we observed significantly higher170 expression levels of PD-1 in COVID-19s patients already during the first 5 days of hospital 171 admission, predominantly affecting the CD4 + T cell compartment, pointing to a potential 172 functional deficit in T helper (Th) cell immune responses (Fig. 2D). While in samples from 173 COVID-19m patients PD-1 expression normalized at TP 5 (week 4-14), it remained elevated 174 on memory CD4 + T cell subsets in COVID-19s (Fig. S2C). In contrast to PD-1, the detected 175 upregulation of the inhibitory receptor CTLA-4 on PMA and ionomycin-restimulated CD4 + 176 effector memory (EM) cells occurred only at later stages of disease (TP 3 and 4; day 6-15) 177 (Fig. 2E, S2D). These findings point to a shared altered innate immune response and signs 178 of hyperinflammation and exhaustion within the T cell compartment across all patients with 179 severe RS.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF3": {
            "text": "In order to interrogate the cytokine polarization, the cells were briefly stimulated in vitro prior181 to spectral flow acquisition. The resulting cytokine profile of stimulated lymphoid 182 subpopulations from COVID-19 patients showed significantly higher amounts of IL-21, as 183 well as a shift towards a cytotoxic phenotype indicated by high levels of granzyme B and 184 perforin in the T and NK cell compartments, relative to HCs (Fig. S2E, S2F, data not shown). the acute phase of disease (TP 1 and 2) (Fig. 2I, S2K, S2L). Single-cell RNA-seq analysis of 195 blood cells from COVID-19 patients -in absence of ex vivo stimulation -revealed strong 196 expression of CSF2 (encoding for GM-CSF) particularly in CD4 + T cells (Fig. S2M). Detailed 197 differentially expressed gene (DEG) analysis of CSF2 high vs. low expressing CD4 + T cells 198 indicated these cells as a hyperinflammatory subset, strongly expressing TNF, IL21, 199 TNFRSF4, GNLY, CD40LG, CCL20, ICAM1 and demonstrating low ANXA1 mRNA levels, 200among others(Fig. S2N).201Overall, these data demonstrate a T cell compartment marked by both hyperinflammatory 202 and exhaustive features shared by patients with severe COVID-19 and non-SARS-CoV-2-203 induced RSs (HAP). Over time, this phenotype persists, particularly in disease courses of 204 COVID-19s(Fig. 2J).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF4": {
            "text": "Phenotypic alterations in innate immune signatures are shared in severe COVID-19 206 and HAP 207 We further characterized the identified DC and NK cell features shared by COVID-19s and 208 HAP (Fig. 3A, Table S3). To reveal the dynamic changes over time, we displayed the 209 COVID-19 cohorts together with HCs as baseline and HAP patients as comparison. Lower 210 expression of HLA-DR in CD56 low CD16 -NK cells suggest a diminished cytotoxic response 211 in COVID-19s (Fig. 3B-D, S3A) (Erokhina et al., 2020). Similarly, COVID-19s displayed 212 reduced frequency of plasmacytoid DCs (pDC) (Fig. 3E-G, S3B). Although the pDC 213 frequency was also different from HAP, the cut-offs of the ES were not reached.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF5": {
            "text": "Upregulation of the Fas receptor CD95 was detected in all DC subsets -particularly on pDCs 215 -at early TPs 1 and 2(Fig. S3C, S3D). This might play a role in the loss of those cells 216 through Fas-mediated apoptosis.217To mimic SARS-CoV-2 infection in vitro, the PBMC samples were stimulated for 8h with the218 TLR7 and TLR8 agonist R848. In response, intermediate and non-classical monocytes as 219 well as conventional DC2s (cDC2s) upregulated expression of the chemokine receptor 220 CCR2 (Fig. S3E, S3F), but only the cDC2-related feature reached the cut-off for being 221 COVID-19s-specific (>0.3 ES vs. COVID-19m) and positively correlated with the severity 222 grade of SARS-CoV-2-mediated disease (Fig. 3H). As CCR2 expression on DCs is a 223 hallmark of inflammation and required for their migration to the inflamed lung (Kvedaraite et 224 al., 2020; Nakano et al., 2017), this could explain the invasion of DCs into the lungs of 225 patients hospitalized with severe COVID-19. The NK and DC-specific dysregulation 226 described here were already apparent during the early phase of the disease, and the vast 227 majority of these changes persisted until TP 5 in severe COVID-19 patients, yet resolved in 228 patients with COVID-19m (Fig. 3I). In line with reduced pDC frequencies, IFN-levels in the 229 J o u r n a l P r e -p r o o f serum of COVID-19s patients showed a robust trend towards reduction, when compared to To summarize, patients with severe RS show signs of diminished cytotoxicity combined with 232 increased cell migration within the NK cell and DC compartment independent of the 233 underlying pathogen. versus other respiratory pathogens 236 After defining several common immunological features characterizing the immune landscape 237 of COVID-19s in common with HAP, we next extracted the features specific to SARS-CoV-2 238 infection. We selected all immune traits characterizing COVID-19s (cut-off ES vs. COVID-239 19m > 0.3) and to further condense the signature uniquely existing in COVID-19s and being 240 different from HAP, we set a strict cut-off ES 0.4 vs. HAP (Fig. 4A,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF6": {
            "text": "245 shared to this extent by patients with mild COVID-19 disease (Fig. 4B, 4C, S4A, S4B). The 246 protein expression of both HLA-DR and CD86 negatively correlated with the severity of 247 COVID-19, with highest significance of this relationship within monocytes (Fig. 4D, 4E, S4C, 248 S4D). Although the apparent paralysis in the APC compartment fulfilled the criteria for249COVID-19s-specificity(Fig. 4F), this was largely driven by a more pronounced APC 250 dysfunction in HAP, when compared to HCs(Fig. 4G, H). Taken together, the emerging 251 overall picture of a myeloid compartment characterized by an impaired APC function -most 252 likely due to emergency myelopoiesis -in COVID-19s. However, the data suggest that this is 253 a feature shared across all patients with severe RS and not specific to the immune response 254 against SARS-CoV-2.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF7": {
            "text": "Distinct signatures of COVID-19s are exclusive to the lymphocyte compartment 256 While most of the alterations in the monocyte and DC compartment were convergent in the 257 two severe RSs, we identified COVID-19s-specific T and NK cell signatures (Fig. 5A, Table 258 S3; ES COVID-19s vs. COVID-19m > 0.3 and vs. HAP > 0.4). A focused analysis of all T cell 259 subsets (Fig. S5A) revealed a dramatic loss of NKT cells in COVID-19s as one of those 260 signatures",
            "latex": null,
            "type": "figure"
        },
        "FIGREF8": {
            "text": "Chronically stimulated T cells overexpress inhibitory receptors including PD-1 and display 271 poor effector capacity (Ahmadzadeh et al., 2009; Crawford et al., 2014; Huang et al., 2019a; 272 Pauken and Wherry, 2015; Wu et al., 2014). By comparing PDCD1 high and low expressing 273 CD4 + T cells using a single-cell RNA-seq dataset (Zhao et al., 2021), we found PDCD1 high 274 CD4 + T cells to express genes associated with exhaustion (HAVCR2, LAG3, CTLA4, TIGIT, 275 BATF) as well as reduced amounts of TCF7, TNF, IL2RA, TNFRSF4, FAS, MIKI67, 276 associated with T cell activation (Fig. S5C). This dataset supports the notion that the T cell 277 compartment in COVID-19 patients is impaired or exhausted.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF9": {
            "text": "281 loss of the regulatory protein CD161 in CD4 -CD8 -(TCR\u03b3\u03b4 enriched) T cells in COVID-19s 282 (Fig. 5E, S5E). This phenomenon is especially intriguing, as CD4 -CD8 -(TCR\u03b3\u03b4 enriched) T 283 cells share the transcriptional signatures of CD161-expressing Mucosa-Associated Invariant 284 T (MAIT) cells, a CD8 + T cell subset resembling innate-like sensors and mediators of 285 antiviral responses (Fergusson et al., 2014, 2016).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF10": {
            "text": "308 exhaustion and altered early antiviral innate lymphoid response specific to the immune 309 response to SARS-CoV-2.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF11": {
            "text": "310 HLA profile links COVID-19 immunopathology to impaired virus recognition 311 After defining the pathological immune landscape specific for SARS-CoV-2 and distinct from 312 other pathogen-induced pneumonias, we next explored the degree of correlation existing 313 across these and other COVID-19s-associated immune features in order to depict the overall 314 immune network underlying COVID-19s. We therefore selected all signatures associated 315 with COVID-19s (ES vs. COVID-19m > 0.3) from TP 1 and 2 and, for each feature, 316 computed Pearson's r correlation values visualized in a heatmap plot for each COVID-19s 317 and HAP (Fig. 6A). Given the power of this multi-dimensional, global analysis tool, it was 318 possible to identify correlation patterns within the immune network of the two investigated 319 conditions, namely COVID-19s and HAP. Focusing on the interactive network underlying 320 early and severe SARS-CoV-2 mediated disease, we discovered distinctive associations 321 between different branches of adaptive and innate immunity, translating into correlation 322 clusters between myeloid and T cells (#1), myeloid and NK cells (#2) as well as T and NK 323 cells (#3)(Fig. 6A). These associations were weak in HAP, further supporting our claim of a 324 SARS-CoV-2 specific immune landscape that characterizes severe disease courses.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF12": {
            "text": "Because of earlier evidence of SARS-CoV-2 peptide binding to Human Leukocyte Antigen 326 (HLA) molecules differs across genotypes (Nguyen et al., 2020), we introduced next 327 generation sequencing (NGS)-based HLA class I typing of 48 patients of our COVID-19 328 cohort. We calculated the predicted number of tightly binding (<50nm) SARS-CoV-2-derived 329 peptides per HLA class I gene (based on every single underlying allele genotype) for each of",
            "latex": null,
            "type": "figure"
        },
        "FIGREF13": {
            "text": "330our typed individuals(Fig. S6A, S6B,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF14": {
            "text": "332single-cell immune profiling analysis and correlated this HLA-A, HLA-B and HLA-C score 50 omics approach allowed us to show that the majority of the severe COVID-19-associated 335 immune features of the innate immune system (e.g. NKT frequency, HLA-DR in monocytes 336 and DCs, etc.) was correlating with the SARS-CoV-2 binding strength(Fig. 6B). Meaning, 337 that efficient HLA binding capacity to SARS-CoV-2 peptides may mitigate the alterations of 338 the innate immune system detected in COVID-19s. Also, the COVID-19s associated GM-339 CSF production in CD8 + CM T cells positively correlated with high HLA scores. To conclude, 340 the data suggests that weak HLA binding to SARS-CoV-2 peptides may at least in part drive 341 the immunopathology in COVID-19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF15": {
            "text": "To translate the complex immune signatures into clinical use, we correlated the COVID-19s-343 defining immune signatures with routine clinical parameters. In order to identify stratifying 344 biomarkers in the very early phase of disease, we included features significantly associated 345 with COVID-19s at TP 1 only. As every COVID-19 patient was graded according to the 346 maximum severity of disease during the longitudinal follow-up of the study and this grading 347 was allocated to every sample of the same patient, the included features of TP 1 fulfil the 348 criteria to be predictive. Several blood values and BMI (indicated by an arrow) were highly 349 correlated with our COVID-19s-defining immune signatures, thereby translating these 350 immunological findings into clinical routine parameters(Fig. 6C). To further validate these 351 promising candidates for outcome prediction, we linearly correlated them with COVID-19 352 severity grade(Fig. 6D, S6C). Although the number of provided values was limited and 353 several associations turned out to be significant but with a low R squared value, LDH and 354 granulocyte counts showed a strong correlation with worsening of COVID-19, thus 355 presenting easily applicable biomarkers(Fig. 6D, S6D).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF16": {
            "text": "359aimed at interrupting the immunopathologic cascade of severe COVID-19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF17": {
            "text": "360ACE2 expression in a CD4 + T cell subset increases after ex vivo stimulation361 SARS-CoV-2 employs the angiotensin-converting enzyme 2 (ACE2) as its receptor for 362 cellular entry (Prompetchara et al., 2020; Zhou et al., 2020). To determine potential entry 363 sites within T cells we measured ACE2 expression across our immune map. We did not 364 identify ACE2 expression in steady state healthy T cell subpopulations, whereas samples 365 from severe RS showed marginal expression, especially in the CD4 + CXCR3 + CCR6 + (Th1",
            "latex": null,
            "type": "figure"
        },
        "FIGREF18": {
            "text": "Th17-enriched) subset(Fig. 7A, 7B, 7C, S7A, S7B) which was significantly reduced in 367 COVID-19s(Fig. 7D). When we profiled the stimulated PBMCs mimicking the COVID-19 368 inflammatory environment, we discovered a CD4 + T cell subpopulation, of whichFig. 7G, 7H, S7C). Further analysis of this subset demonstrated no relevant overlap with a 372 specific cytokine polarization profile or FOXP3 expression (Fig. S7D, S7E). The presence of 373 ACE2 expression on an activated CD4 + T cell subset may provide a mechanism for virus 374 entry and contribution to the immunopathological network of COVID-19. of two cohorts of severe infectious RSs (COVID-19s and HAP) driven by 377 different pathogens allowed us to uncover unique immune signatures in SARS-CoV-2 378 mediated disease. Recent data describes the immunopathogenesis of HAP as critical 379 illness-related immuno-suppression (Roquilly et al., 2019) mainly characterized by 380 alterations in the IL-12 -IFN-\u03b3 axis (Roquilly et al., 2017). Conversely, the COVID-19 381 immune response includes traits also occurring in other severe RS triggered by other 382 pathogens such as influenza (Lee et al., 2020; Tian et al., 2020). However, mainly due to the 383 small cohort sizes and lack of a comparable control group of patients suffering from non-384 SARS-CoV-2 driven severe RS, the COVID-19-specific immune signature remains elusive.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF19": {
            "text": "Within our dataset already, a global PCA analysis of all immunophenotypes allowed for a 386 clear separation between COVID-19s, COVID-19m, HAP and HCs. There was however a 387 partial overlap between COVID-19s and HAP, revealing some core immune features 388 associated with severe RS independent from the disease etiology.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF20": {
            "text": "Whilst previous studies described an impairment in the monocyte and DC compartment to390 be decisive for a severe COVID-19 course (Arunachalam et al., 2020; Kuri-Cervantes et al., 391 2020; Merad and Martin, 2020; Silvin et al., 2020), features which we confirmed here, those 392 were found to not be exclusive to SARS-CoV-2-immunopathology. We confirmed loss of 393 HLA-DR and CD86 expression in APCs, a finding associated with emergency myelopoiesis, 394 where newly emerging myeloid cells show reduced APC capacity (Schulte-Schrepping et al., 395 2020). Recent data shows the secretion of CCL2 by airway macrophages and a concomitant 396 upregulation of the CCL2-receptor CCR2 in peripheral blood monocytes of SARS-CoV-2 397 infected patients; thus, extensive accumulation of monocytes and macrophages within 398 alveolar spaces in COVID-19 lung autopsies suggests recruitment from circulation (Szabo et 399 al., 2020). Our data support this, but in addition we observed that cDC2s also upregulated 400 CCR2 expression with an even greater ES than monocytes. There is evidence for CCR2 401 being required for DC migration to the inflamed lung, respectively, while this is not the case 402 in the steady state condition (Nakano et al., 2015, 2017). Thus, the declining number of 403 cDC2s in the systemic circulation of COVID-19 patients may be a reflection of cDC2 404 extravasation into the affected lungs.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF21": {
            "text": "Alongside signatures shared in severe RS, we also extracted those specific to and unique in406 COVID-19s. These SARS-CoV-2-induced adaptations were restricted to the T and NK cell 407 compartment. Several studies described an upregulation of PD-1 and CD38 alongside other 408 activation and exhaustion markers, suggesting a hyperactivated and exhausted T cell 409 compartment (De Biasi et al., 2020; Chen and Wherry, 2020). However, again, it was 410 unclear as to whether this emerging pattern in lymphocytes is the result of severe RS in 411 general, or is specific to the immunopathology induced by SARS-CoV-2. We here describe an overall picture of T cell exhaustion and altered early antiviral innate lymphoid response unique to COVID-19s. transmembrane receptor ACE2, which is predominantly expressed in epithelial cells of the 416 lung, intestine and endothelial cells (Varga et al., 2020). Our analysis revealed the ability of 417 highly activated CD4 + T cells to express ACE2. Others also detected ACE2 positive 418 lymphocytes in lungs COVID-19 patients (Ackermann et al., 2020; chen et al., 2020).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF22": {
            "text": "Moreover, CD4 + Th cell infection by SARS-CoV-2 occurs in an ACE2 dependent manner 420 (Pierce et al., 2020; Pontelli et al., 2020). Compared to SARS-CoV, SARS-CoV-2 has a 10 -421 20-fold higher affinity for host membrane ACE2 (Wrapp et al., 2020). Thus, even low ACE2 422 expression may be sufficient for viral entry. A direct infection of responding lymphocytes, 423 leading to cell death and impaired SARS-CoV-2 clearance, goes in line with higher 424 peripheral blood viral load positively correlating with COVID-19 severity (Han et al., 2020). In 425 conclusion, the ability for SARS-CoV-2 to directly infect T cells provides yet another potential 426 mechanism to describe the immunopathology of COVID-19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF23": {
            "text": "The cytokine storm in COVID-19 is pronounced as one of the driving immunopathological428 features in SARS-CoV-2 mediated disease worsening (Merad and Martin, 2020; Moore and higher frequencies of IL-6 and TNF (Del Valle et al., 2020), for which high plasma levels 431 were described in COVID-19 patients, indicating neutrophils, monocytes and endothelial 432 cells at the site of infection likely account for the dysregulated cytokine production.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF24": {
            "text": "Nevertheless, we identified the cellular sources for GM-CSF as predominantly the CD4 + and 434 CD8 + TEMRA subset -a feature of severe COVID-19 sharing with HAP -and documented435 correlation of the expression with COVID-19 severity. Our data complement two recent 436 reports, which show that in particular lung invading T cells express GM-CSF (by using 437 scRNA-seq) (Zhao et al., 2021) and that GM-CSF serum levels are elevated in COVID-19 438 patients (Thwaites et al., 2021). Supportive, elevated circulating GM-CSF + CD4 + T cell levels 439 are predictive of poor outcomes in sepsis patients (Huang et al., 2019b). Collectively, this 440 suggests GM-CSF to be an early driver of the underlying immunopathological cascade in 441 COVID-19s, thereby being a promising therapeutic target (NRI, GEM TRIAL, Clinical trial 442 identifiers NCT04400929 and NCT04411680, (Bonaventura et al., 2020; Bosteels et al., 443 2020; Lang et al., 2020; De Luca et al., 2020)).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF25": {
            "text": "NGS-based HLA-typing and further integration of this dataset into our single-cell immune alterations were less pronounced in patients with predicted high HLA class I binding 448 capacity to SARS-CoV-2 peptides, GM-CSF production in CD8 + CM T cells -a feature 449 associated with severe COVID-19 disease -was increased. The occurrence of both mild and 450 severe COVID-19-associated immune features in patients with strong SARS-CoV-2 451 recognition (high HLA score 50) could further explain the inconsistent reports which attempt 452 to link HLA class I binding capacity to SARS-CoV-2 peptides to COVID-19 severity 453 (Ellinghaus et al., 2020; Iturrieta-Zuazo et al., 2020). By combining the single-cell immune 454 mapping with HLA genetics, we uncovered a link between the HLA profile and impaired virus 455 recognition in COVID-19.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF26": {
            "text": "Due to emerging follow-up studies, an increased number of COVID-19 patients are 457 described to experience prolonged symptomatology. This phenomenon, referred to as \"long458 COVID\" affects around 10% of the cases. An attributed reason for long-lasting complaints is 459 persistent tissue damage in severe cases. Nevertheless, patients following mild SARS-CoV-460 2 infections also suffer from prolonged symptoms (Iadecola et al., 2020; Mahase, 2020). We 461 identified several immune features, predominantly of the T and NK compartment, which did 462 not rebound at the end of our study, several weeks after infection. Thus, prolonged immune 463 dysregulation, long after primary pathogen encounter, could play a role in \"long COVID\".",
            "latex": null,
            "type": "figure"
        },
        "FIGREF27": {
            "text": "An additional aspect of our study was to identify predictive biomarkers of severe COVID-19465 patient outcomes. An earlier study identified the frequency of circulating MAIT cells to have 466 predictive value (Flament et al., 2021). Here we identified a dramatic, early loss of NKT cells 467 in the circulating immune compartment of COVID-19s. While others confirmed this 468 observation (Zhang et al., 2020a; Zingaropoli et al., 2020), here we found this phenomenon 469 indeed to not be shared across severe RS patients but being specific to the SARS-CoV-2 470 immune response. NKT cells are important for the production of an early wave of IL-4 471 promoting germinal center (GC) formation during viral infection. Delay in GC formation in 472 COVID-19 patients may be a direct consequence of NKT cell migration to the airways 473 (Dempsey, 2018; Fontana and Pepper, 2018; Jouan et al., 2020; Kaneko et al., 2020).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF28": {
            "text": "Translation of this finding into clinical routine diagnostics can easily be implemented using 475 CD3 and CD56 to calculate NKT cell frequencies upon hospital admission. Across our three 476 independent COVID-19 cohorts, a cut-off set to 2.3% for NKT cell frequencies (among T 477 cells) would have identified all patients who later developed severe disease. Early 478 identification of patients at risk could help to tailor their treatment and improve the outcome.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF29": {
            "text": "479LIMITATIONS OF THE STUDY480While we initially anticipated center-specific batch effects in our multi-center study, this was481 not the case. However, our HAP cohort consists of patients suffering from severe pneumonia 482 J o u r n a l P r e -p r o o f to a pure viral pneumonia cohort could help to further specify the unique immune signatures 484 to SARS-CoV-2 and distinctive to other viruses. Using PBMCs as source of analyzed 485 immune cells allows for easy implementation of our findings (such as NKT frequency as 486 predictive biomarker) to the clinics. Even though the simple measurement of circulating NKT 487 cell frequencies would have predicted all of our COVID-19 patients who developed severe 488 disease, larger follow-up studies are needed to solidify this measurement as the Clinical Research Center 1436 and the Delegation for clinical research and 495 innovation of the Toulouse University Hospital for their highly valuable implication. We thank 496 the biological resource centre for biobanking (CHU Nantes, Nantes Universit\u00e9, Centre de 497 ressources biologiques (BB-0033-00040), F-44000 Nantes, France).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF30": {
            "text": "CRSII5_183478 to B.B., 31CA30_195883 to S.Kreutmair, M.C., M.B.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF31": {
            "text": "500 and B.B.), The LOOP Zurich, the Vontobel foundation (to B.B.), the the European Union's 501 Horizon 2020 research and innovation programme under grant agreement No 847782 (to 502 B.B. and A.R.) and the European Research Council (ERC; No 882424) to B.B., the Agence 503 National de la Recherche (ANR) and Region Pays de la Loirer -Flash COVID-504 19:COVARDS project (to A.R.) and the French Ministry of Health with the participation of the 505 Groupement Interr\u00e9gional de Recherche Clinique et d'Innovation Sud-Ouest Outre-Mer 506 (PHRCI 2020 IMMUNOMARK-COV) (to R.L. and G.M.-B.). S.Kreutmair is a recipient of a 507 postdoctoral fellowship of the Deutsche Forschungsgemeinschaft (DFG). N.G.N. is a 508 recipient of a University Research Priority Program (URPP) postdoctoral fellowship. F.I.509received a PhD fellowship from the Studienstiftung des deutschen Volkes. We thank Dr.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF32": {
            "text": "Robinson from Insight Editing London for critical review and editing of the manuscript.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF33": {
            "text": ", B.B., S.Kreutmair, S.U., N.G.N., C.A., D.D.F. and A.R.; Methodology, 513 S.Kreutmair, S.U., N.G.N. and F.I.; Formal Analysis, S.Kreutmair, S.U., N.G.N., F.I., M.K., 514 S.B.; Investigation, S.Kreutmair, S.U., N.G.N., F.I., C.A., D.D.F.; Resources, B.B., A.R., 515 M.B., G.M.-B., R.L., M.C.; Sample and patient data collection and processing, S.Kreutmair, 516 B.G., I.A., S.A.-H., J.N., M.B., G.M.-B., M.L., N.P.J., M.K., N.P.M., S.G., P.R., H.A.H.; Data 517 Curation, S.Kreutmair, S.U., N.G.N., F.I., C.A., D.D.F., E.F.; Writing -Original Draft, 518 S.Kreutmair, S.Krishnarajah and B.B.; Writing -Review & Editing, S.Kreutmair, S.U., 519 N.G.N., F.I., C.A., D.D.F., S.Krishnarajah, M.K., E.F., S.B., B.G., M.L., N.P.J., N.P.M., S.G.,",
            "latex": null,
            "type": "figure"
        },
        "FIGREF34": {
            "text": ".R., H.A.H., I.A., S.A.-H., J.N., M.C., R.L., G.M.-B., M.B., A.R. and B.B.; Visualization, 521 S.Kreutmair, N.G.N., F.I. and M.K.; Funding Acquisition and Supervision, M.C., R.L., G.M.-522 B., M.B., A.R., and B.B. Immunomonitoring reveals differing immune landscapes in COVID-19m, 525 COVID-19s and HAP patients 526 A: Schematic of experimental approach.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF35": {
            "text": "UMAP with FlowSOM overlay showing total CD45 pos cells of combined samples. 1000 528 cells were subsetted from every sample from each cohort.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF36": {
            "text": "PCA of the total immune compartment based on marker expression in the surface panel.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF37": {
            "text": "Comparison of immune features derived from each leukocyte subpopulation between 531 experimental groups. A dot plot displaying the ES calculated in HAP vs. COVID-19s (x axis; 532 threshold 0.4) compared to the ES calculated in COVID-19m vs. COVID-19s (y axis; 533 threshold 0.3). Each dot represents one immunological feature, colors represent the 534 leukocyte compartment they refer to.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF38": {
            "text": "Proportion of each immune compartment (normalized to input) in the identified sets of 536 immune features highlighted in Fig. 1D.537See alsoFigure S1.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF39": {
            "text": "Shared T cell features between severe pathogen-induced RSs highlight the 539 emergence of hyperinflammatory and exhausted subsets in COVID-19s 540 A: Comparison of immune features derived from each leukocyte subpopulation between 541 experimental groups. A dot plot displaying the ES calculated in HAP vs. COVID-19s (x axis; 542 threshold 0.4) compared to the ES calculated in COVID-19m vs. COVID-19s (y axis; 543 threshold 0.3). Each dot represents one immunological feature. The red box highlights 544 immune features, which are associated with severe RS (COVID-19s and HAP), with a focus 545 on changes within the T cell fraction.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF40": {
            "text": "UMAP with FlowSOM overlay of total T cells of combined samples. 1000 cells were 547 subsetted from every sample from each cohort. T cell subsets with transparent names do not 548 contain immune features highlighted inFig. 2A.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF41": {
            "text": "Median frequencies and 25th and 75th percentile of FlowSOM-generated CD4 -CD8 -550 (TCR\u03b3\u03b4 enriched) immune cell cluster.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF42": {
            "text": "Median expression and 25th and 75th percentile of PD-1 in FlowSOM-generated immune 552 cell clusters shown in B. E: Median expression of CTLA-4 within CD4 + EM T cell subset of HCs shown in greyMedian frequency and 25th and 75th percentile of IFN-\u03b3 positive cells in FlowSOM-560 generated immune cell clusters shown in F.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF43": {
            "text": "Median frequency and 25th and 75th percentile of IL-2 positive cells in FlowSOM-562 generated immune cell cluster shown in F.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF44": {
            "text": "Correlation between frequency of GM-CSF expressing CD4 + (left panel) and CD8 + (right 564 panel) TEMRA cells and the severity grade of COVID-19 patients in combined TPs 1 and 2.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF45": {
            "text": "Heatmap depicting the z-score of each T cell related immune feature (highlighted in Fig. 566 2A) when compared to HCs for every TP. Both negative and positive changes are visualized 567 by intensity of red color scale. MFI = Mean fluorescence intensity.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF46": {
            "text": "Mann-Whitney test, BH correction). See alsoFigure S2.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF47": {
            "text": "Phenotypic alterations in innate immune signatures are shared in severe 571 COVID-19 and HAP 572 A: Comparison of immune features derived from each leukocyte subpopulation between 573 experimental groups. A dot plot displaying the ES calculated in HAP vs. COVID-19s (x axis; 574 threshold 0.4) compared to the ES calculated in COVID-19m vs. COVID-19s (y axis; 575 threshold 0.3). Each dot represents one immunological feature. The red box highlights 576 immune features, which are associated with severe RS, with a focus on changes within the 577 monocyte, DC and NK cell fraction.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF48": {
            "text": "UMAP with FlowSOM overlay of total NK cells of combined samples. 1000 cells were 579 subsetted from every sample from each cohort. NK cell subsets with transparent names do 580 not contain immune features highlighted in Fig. 3A.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF49": {
            "text": "Median expression of various markers in FlowSOM-derived clusters shown in B.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF50": {
            "text": "Median expression and 25th and 75th percentile of HLA-DR in FlowSOM-generated 583 CD56 low CD16 -NK cell cluster shown in B, combined for TP 1 and 2 (left panel) or displayed 584 for every individual TP (right panel). 585 J o u r n a l P r e -p r o o f E: UMAP with FlowSOM overlay of total monocytes and DCs of combined samples. 1000 586 cells were subsetted from every sample from each cohort. Monocyte and DC subsets with 587 transparent names do not contain immune features highlighted in Fig. 3A. 588 F: Median expression of various markers in FlowSOM-derived clusters shown in E. 589 G: Median frequencies and 25th and 75th percentile of FlowSOM-generated pDC immune 590 cell cluster.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF51": {
            "text": "Correlation between median expression of CCR2 in cDC2s following TLR7 and TLR8 592 stimulation against the severity grade of COVID-19 patients. All TPs have been pooled in the 593 left panel, and individual TPs depicted in the right panel.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF52": {
            "text": "Heatmap depicting the z-score of each monocyte and DC related immune feature 595 (highlighted in Fig. 3A) when compared to HCs for every TP. Both negative and positive 596 changes are visualized by intensity of red color scale. MFI = Mean fluorescence intensity.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF53": {
            "text": "and **** = p < 0.0001, Mann-Whitney test, BH correction). See alsoFigure S3.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF54": {
            "text": "Impaired antigen-presentation distinguishes the immune response to SARS-600 CoV-2 versus other respiratory pathogens 601 A: Comparison of immune features derived from each leukocyte subpopulation between 602 experimental groups. A dot plot displaying the ES calculated in HAP vs. COVID-19s (x axis; 603 threshold 0.4) compared to the ES calculated in COVID-19m vs. COVID-19s (y axis; 604 threshold 0.3). Each dot represents one immunological feature. The red box highlights 605 immune features, which are different in COVID-19s and HAP, with a focus on changes within 606 monocytes and DCs. 607 Median expression of HLA-DR (B) or CD86 (C) within classical monocytes of HCs shown in 608 grey, HAP patients in blue, and COVID-19m and COVID-19s patients across TPs 1-5 shown 609 in red.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF55": {
            "text": "Correlation between median expression of HLA-DR (D) or CD86 (E) in monocytes or DCs (TP 1 and 2 pooled) against the severity grade of COVID-19 patients.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF56": {
            "text": "Heatmap depicting the z-score of each monocyte and DC related immune feature 613 (highlighted inFig. 4A) when compared to HCs for every TP. Both negative and positive",
            "latex": null,
            "type": "figure"
        },
        "FIGREF57": {
            "text": "614changes are visualized by intensity of red color scale.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF58": {
            "text": "Distinct signatures of COVID-19s are exclusive to the lymphocyte 620 compartment 621 A: Comparison of immune features derived from each leukocyte subpopulation between 622 experimental groups. A dot plot displaying the ES calculated in HAP vs. COVID-19s (x axis; 623 threshold 0.4) compared to the ES calculated in COVID-19m vs. COVID-19s (y axis; 624 threshold 0.3). Each dot represents one immunological feature. The red box highlights 625 immune features, which are different in COVID-19s and HAP, with a focus on changes within 626 T and NK cells.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF59": {
            "text": "Median frequencies and 25th and 75th percentile of FlowSOM-generated NKT immune 628 cell cluster.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF60": {
            "text": "Correlation between median expression of PD-1 in CD4 + EM cells (TP 1 and 2 pooled) 630 against the severity grade of COVID-19 patients.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF61": {
            "text": "Correlation between median expression of CD38 in CD4 -CD8 -(TCR\u03b3\u03b4 enriched) and 632 CD4 + EM T cells (TP 1 and 2 pooled) against the severity grade of COVID-19 patients.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF62": {
            "text": "Median expression and 25th and 75th percentile of CD161 in FlowSOM-generated CD4 -634 CD8 -(TCR\u03b3\u03b4 enriched) immune cell cluster.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF63": {
            "text": "Correlation between median expression of CD95 in CD56 high NK cells (TP 1 and 2 pooled) 636 against the severity grade of COVID-19 patients.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF64": {
            "text": "Schematic overview of cytokine polarization profile comparing COVID-19s and COVID-638 19m. UMAP with FlowSOM overlay shows cytokine-producing T cells (features reaching an 639 ES > 0.3 vs COVID-19m and > 0.4 vs HAP). 1000 T cells were subsetted from every sample 640 from each cohort.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF65": {
            "text": "Median frequency and 25th and 75th percentile of IFN-\u03b3 positive cells in FlowSOM-642 generated immune cell clusters shown in G.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF66": {
            "text": "Heatmap depicting the z-score of each T and NK cell related immune feature (highlighted 644 in Fig. 5A) when compared to HCs for every TP. Both negative and positive changes are 645 visualized by intensity of red color scale. MFI = Mean Fluorescence Intensity.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF67": {
            "text": "Median frequencies or expression of indicated populations and markers. Boxplots show 647 the 25th and 75th percentile.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF68": {
            "text": "HLA profile links COVID-19 immunopathology to impaired virus recognition 651 A: Correlogram of all immune features (TP 1 and 2) with ES COVID-19s vs. COVID-19m > 652 0.3, shown for COVID-19s and HAP. Red arrows highlight immune features unique in 653 COVID-19s (ES vs. HAP > 0.4). The black boxes #1-3 highlight highly correlating immune 654 clusters. 655 B: Correlogram of immune features from TP 1 only with ES COVID-19s vs. COVID-19m > 656 0.3 with HLA score 50. HLA score 50 represents the number of predicted tightly binding 657 SARS-CoV-2 peptides of both HLA alleles of a patient. Red arrows highlight SARS-CoV-2-658 specific immune features (ES COVID-19s vs. HAP > 0.4).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF69": {
            "text": "Correlogram of immune features from TP 1 only with ES COVID-19s vs. COVID-19m > 660 0.3 with routinely assessed clinical parameters. Red arrows highlight highly correlating 661 parameters.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF70": {
            "text": "Correlation between LDH and granulocyte counts (TP 1 only) against the severity grade 663 of COVID-19 patients.664See alsoFigure S6.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF71": {
            "text": "ACE2 expression in a CD4+ T cell subset increases after ex vivo stimulation 666 A: Comparison of immune features derived from each leukocyte subpopulation between 667 experimental groups. A dot plot displaying the ES calculated in HAP vs. COVID-19s (x axis) 668 compared to the ES calculated in COVID-19m vs. COVID-19s (y axis). Each dot represents 669 one immunological feature. The red box highlights the immune feature focused in this figure.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF72": {
            "text": "Median expression of indicated markers in FlowSOM-derived clusters of unstimulated 671 samples.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF73": {
            "text": "Median frequency and 25th and 75th percentile of ACE2 positive cells in a subset of 673 unstimulated CXCR3 + CCR6 + (Th1 Th17-enriched) CD4 + T cells. All TPs have been pooled.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF74": {
            "text": "Median frequency and 25th and 75th percentile of CXCR3 + CCR6 + (Th1 Th17-enriched)675CD4 + T cells at each TP.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF75": {
            "text": "Representative plot showing ACE2 and isotype staining within the T cell compartment of PMA and ionomycin restimulated (5h) COVID-19 samples.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF77": {
            "text": "Median expression and 25th and 75th percentile of PD-1 (left panel) and CTLA-4 (right 684 panel) in FlowSOM-generated immune cell clusters after PMA and ionomycin restimulation 685 (5h). All TPs have been pooled.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF78": {
            "text": "human CD3 (UCHT1), BUV805 BD Cat# 565515; RRID:AB_2739277 anti-human CD33 (WM53), BUV395 BD Cat# 740293; RRID:AB_2740032 anti-human CD38 (HIT2), APC-Cy5.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF79": {
            "text": "vivo Reactivation of PBMCs 742 PBMCs collected in clinics were kept in cell culture medium (RPMI-1640, 10% fetal bovine 743 serum (FBS; Gibco), and 1\u00d7 l-glutamine (Gibco) and 1\u00d7 penicillin streptomycin (Gibco)) 744 supplemented with 5U ml\u22121 benzonase (Sigma-Aldrich) and frozen in liquid nitrogen until 745 experimental analysis. Then, for spectral flow analysis, cells were thawed using Cryo thaw 746 devices (Medax). Briefly, cells were resuspended in cell culture medium supplemented with 747 2U ml \u22121 benzonase by centrifugation (300 r.c.f.; 7 min; 24 \u00b0C). Cell count was calculated 748 using an automated cell counter (Bio-Rad). Due to the resulting cell count, cells were used 749 for all panels or surface panel only. Subsequent procedure including short-term reactivation 750 of cryopreserved PBMCs and cytometry analysis were performed as described previously 751 (Galli et al., 2019; Hartmann et al., 2016). Briefly, 2 million (mio) cells were directly stained 752 for cytometry analysis (surface panel), while 1 mio cells were restimulated with 50 ng ml \u22121 753 phorbol 12-myristate 13-acetate (Sigma-Aldrich) and 500 ng ml \u22121 ionomycin (Sigma-Aldrich) 754 in the presence of 1\u00d7 Brefeldin A and 1x Monensin (both BD Biosciences) for 5 h at 37\u00b0C or 755 in case of R848 stimulation, 2.5 mio cells using 2\u00b5g ml \u22121 R848 (Invivogen) in the presence of 756 1\u00d7 Brefeldin A and 1x Monensin (both BD Biosciences) for 8 h at 37\u00b0C.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF80": {
            "text": "spectral cytometry, samples were washed in PBS and then resuspended in 100\u00b5l of Live 759 Dead Fixable Blue mixture (Thermo Scientific, 1:500) followed by a washing step. To avoid 760 nonspecific binding, the samples were resuspended in 30 \u00b5l of True Stain FcX (BioLegend) 761 and incubated for 10 min at 4\u00b0C. Anti-human flow cytometric antibodies were purchased pre-762 conjugated (Table S2A-C). 70 \u00b5l of the first surface-antibody mixture was added and cells 763 were incubated for 15 min at 37\u00b0C",
            "latex": null,
            "type": "figure"
        },
        "FIGREF81": {
            "text": ". Then, 765 fixation was performed using 150 \u00b5l of 2% PFA for 15 min at 4\u00b0C.766 Intracellular Cytokine Labeling for Spectral Flow Cytometry 767 J o u r n a l P r e -p r o o f permeabilized using Cytofix Cytoperm reagent (BD Biosciences) for 30 min at 4\u00b0C.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF82": {
            "text": "DNA extraction the DNA easy blood and tissue kit from Quiagen was used. HLA typing 774 was performed using next generation sequencing (NGS) with the NGSgo-AmpX v2 HLA kits 775 (GenDx, Utrecht, Netherlands), and sequenced on an Illumina MiniSeq (Illumina, San Diego, 776 CA). Sequence data were analyzed with NGSengine (GenDx, Utrecht, Netherlands). For 777 samples with low DNA amount, HLA typing was also performed using sequence specific 778 oligomers (SSO) with the LABType kits (One Lambda, Canoga Park, CA). The bead-based 779 analysis was run on a LABScan 3D instrument (Luminex, Austin, TX) and analyzed using the 780 Fusion Software (One Lambda, Canoga Park, CA). All assays were performed according to 781 the manufacturer's recommendations.782 QUANTIFICATION AND STATISTICAL ANALYSIS 783 Acquisition and Preprocessing of Spectral Flow Cytometry Data 784 Spectral cytometry samples were acquired on a Cytek Aurora (Cytek Biosciences). Quality 785 control of the Cytek Aurora was performed daily as instructed by the manufacturer. For 786 downstream analysis, dead cells and doublets were excluded using FlowJo (TreeStar).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF83": {
            "text": "Samples with viability lower than 10% and fewer than 500 live, CD45 positive cells were788 excluded. Cytometry data were transformed with an inverse hyperbolic sine (arcsinh) 789 function using the R environment (range 30 -18000). To balance the influence of markers 790 with different dynamic ranges, we performed background subtraction and channel-based 791 percentile normalization using the 99.9th percentile of each marker across the whole dataset 792 (Bendall et al., 2011). Individual cytokine positivity thresholds were determined based on the 793 99 th percentile of the residual staining in an unstimulated or isotype-stained control sample.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF84": {
            "text": "Algorithm-based High-dimensional Analysis of Spectral Flow Cytometry Data795Pre-processed data were downsampled to a maximum of 150'000 cells per donor for the 796 analysis of the main populations, all cells were used for analysis of the specific immune 797 compartments. The high dimensional analysis was carried out using the R environment,798 based loosely on the workflow described previously (Mair et al., 2016). Two-dimensional 799 UMAP (Uniform Manifold Approximation and Projection) projections were calculated using was performed on the whole dataset to enable identification of small populations, and the 802 results were overlaid on the dimensionality reduction maps (Van Gassen et al., 2015). 803 Principal component analysis was carried out in the stats package using the median 804 activation marker expression of all detected leukocyte subsets. The circles represent the 805 core areas added by the default confidence interval of 68%, which facilitates the separation 806 based on the PC1/2 explanatory rate of the overall difference in measured immune features. 807 For the correlogram, Pearson's r correlation coefficients were computed using the Hmisc 808 package and the resulting correlation matrix was visualized using the corrplot package. All 809 other plots were drawn using ggplot2. For longitudinal visualization, smoothed conditional 810 mean of the feature from the combined COVID-19 cohort was added in light grey.811 Calculation of HLA Score 50 812 Based on the study data of Nguyen et al. (Nguyen et al., 2020), the predicted HLA class I 813 binding capacity to SARS-CoV-2-derived peptides per patient was calculated by counting the 814 number of all SARS-CoV-2-derived peptides which were predicted to be bound by each 815 specific HLA allele. The score 50 includes all SARS-CoV-2 peptides which were predicted 816 for tight binding (<50nm) to the indicated HLA class I allele. The final HLA score 50 per 817 patient represents the total number of tight binding SARS-CoV-2 peptides of both alleles of 818 the patient for HLA-A, HLA-B or HLA-C.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF85": {
            "text": "Single-cell RNA-seq Analysis820For single-cell RNA-seq analysis we used a publicly available dataset of sorted CD45 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167118), of which 5'-RNA single 823 cell transcriptome (10x genomics) was performed. For preprocessing, the feature-barcode 824 matrices for all the sample were further processed by the R package Seurat (v3.1.4). As a 825 quality-control (QC) step, we first filtered out the cells in which less than 200 genes were 826 detected in the blood samples. To remove potential doublets, we excluded cells with total 827 number of detected genes more than 5000. Low-quality cells with more than 5%828 mitochondrial genes of all detected genes were removed. The LogNormalize method in 829 Seurat was used to normalize the scRNA-seq and batch effect correction was performed 830 using Harmony. The R package SingleR, an automatic annotation method for single-cell 831 RNA sequencing (Aran et al., 2019) were then used to determine the cell types. The 832 differential expression between selected groups were calculated by the FindAllMarkers 833 function (min.pct = 0.25, logfc.threshold = 0.25, Wilcoxon rank sum tests).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF86": {
            "text": "compared with the non-parametric Mann-Whitney-Wilcoxon test and summary() functions. P values of less than 0.05 were considered significant and are 840 indicated by an asterisk (*) or the numerical value on the respective graphs. Thrombosis, and Angiogenesis in Covid-19. N. Engl. J. Med. 383, 120-128.857 Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., Wunderlich, J.R., Dudley, M.E., White, 858 D.E., and Rosenberg, S.A. (2009). Tumor antigen-specific CD8 T cells infiltrating the tumor 859 express high levels of PD-1 and are functionally impaired. Blood 114, 1537-1544.860 Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R.P., 861 Wolters, P.J., Abate, A.R., et al. (2019). Reference-based analysis of lung single-cell 862 sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163-172.863 Armstrong, R.A., Kane, A.D., and Cook, T.M. (2020). Outcomes from intensive care in 864 patients with COVID-19: a systematic review and meta-analysis of observational studies. 865 Anaesthesia 75, 1340-1349.866 Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R.A.P.M., Scott, M., Hagan, T., 867 Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., et al. (2020). Systems biological 868 assessment of immunity to mild versus severe COVID-19 infection in humans. Science 369, 869 1210-1220.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF87": {
            "text": "Bastard, P., Rosen, L.B., Zhang, Q., Michailidis, E., Hoffmann, H.-H., Zhang, Y., Dorgham, 871 K., Philippot, Q., Rosain, J., B\u00e9ziat, V., et al. (2020). Autoantibodies against type I IFNs in 872 patients with life-threatening COVID-19. Science (80-. ). 370, eabd4585.873 Bendall, S.C., Simonds, E.F., Qiu, P., Amir el, A.D., Krutzik, P.O., Finck, R., Bruggner, R. V, 874 Melamed, R., Trejo, A., Ornatsky, O.I., et al. (2011). Single-cell mass cytometry of 875 differential immune and drug responses across a human hematopoietic continuum. Science 876 (80-. ). 332, 687-696.877 De Biasi, S., Meschiari, M., Gibellini, L., Bellinazzi, C., Borella, R., Fidanza, L., Gozzi, L., 878 Iannone, A., Lo Tartaro, D., Mattioli, M., et al. (2020). Marked T cell activation, senescence, 879 exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat.880 Commun. 11, 3434.881 Bonaventura, A., Vecchi\u00e9, A., Wang, T.S., Lee, E., Cremer, P.C., Carey, B., Rajendram, P.,882 Hudock, K.M., Korbee, L., Van Tassell, B.W., et al. (2020). Targeting GM-CSF in COVID-19 883 Pneumonia: Rationale and Strategies. Front. Immunol. 11, 1625.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF88": {
            "text": "Bosteels, C., Maes, B., Van Damme, K., De Leeuw, E., Declercq, J., Delporte, A., 885 Demeyere, B., Vermeersch, S., Vuylsteke, M., Willaert, J., et al. (2020). Sargramostim to 886 treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC)is linked to MAIT cell activation and cytotoxicity. Nat. Immunol. 22, E., Friebel, E., Ingelfinger, F., Unger, S., N\u00fa\u00f1ez, N.G., and Becher, B. (2019). The end 925 of omics? High dimensional single cell analysis in precision medicine. Eur. J. Immunol. 49, Gassen, S., Callebaut, B., Van Helden, M.J., Lambrecht, B.N., Demeester, P., Dhaene, 928 T., and Saeys, Y. (2015). FlowSOM: Using self-organizing maps for visualization and 929 interpretation of cytometry data. Cytom. Part A 87, 636-645.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF89": {
            "text": "Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Pere, H., Charbit, B., Bondet, 931 V., Chenevier-Gobeaux, C., Breillat, P., et al. (2020). Impaired type I interferon activity and 932 exacerbated inflammatory responses in severe Covid-19 patients. MedRxiv 933 2020.04.19.20068015.934 Han, M., Xu, M., Zhang, Y., Liu, Z., Li, S., He, T., Li, J., Gao, Y., Liu, W., Li, T., et al. (2020).935 Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients 936 revealed initial immune status as a major determinant of disease severity. Med. Microbiol.937 Immunol. 209, 657-668.938 Hartmann, F.J., Bernard-Valnet, R., Queriault, C., Mrdjen, D., Weber, L.M., Galli, E., Krieg, 939 C., Robinson, M.D., Nguyen, X.H., Dauvilliers, Y., et al. (2016). High-dimensional single-cell 940 analysis reveals the immune signature of narcolepsy. J Exp Med 213, 2621-2633.941 Huang, A.C., Orlowski, R.J., Xu, X., Mick, R., George, S.M., Yan, P.K., Manne, S., Kraya, 942 A.A., Wubbenhorst, B., Dorfman, L., et al. (2019a). A single dose of neoadjuvant PD-1 943 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454-461.944 Huang, H., Wang, S., Jiang, T., Fan, R., Zhang, Z., Mu, J., Li, K., Wang, Y., Jin, L., Lin, F., et 945 al. (2019b). High levels of circulating GM-CSF(+)CD4(+) T cells are predictive of poor 946 outcomes in sepsis patients: a prospective cohort study. Cell. Mol. Immunol. 16, 602-610.947 Iadecola, C., Anrather, J., and Kamel, H. (2020). Effects of COVID-19 on the Nervous 948 System. Cell 183, 16-27.e1.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF90": {
            "text": "Zuazo, I., Rita, C.G., Garc\u00eda-Soid\u00e1n, A., de Malet Pintos-Fonseca, A., Alonso-950 Alarc\u00f3n, N., Pariente-Rodr\u00edguez, R., Tejeda-Velarde, A., Serrano-Villar, S., Casta\u00f1er-951 Alabau, J.L., and Nieto-Ga\u00f1\u00e1n, I. (2020). Possible role of HLA class-I genotype in SARS-952 CoV-2 infection and progression: A pilot study in a cohort of Covid-19 Spanish patients. 953 J o u r n a l P r e -p r o o f (CFR) for COVID-19 among countries. MedRxiv 2020.04.21.20073791. promotes accumulation of conventional dendritic cells in the lung during inflammation (CAM4P.149). J. Immunol. 194, 185.7 LP-185.7. Fontanet, A., Cauchemez, S., and Salje, H. (2020). Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy",
            "latex": null,
            "type": "figure"
        },
        "FIGREF91": {
            "text": "Figure S2",
            "latex": null,
            "type": "figure"
        },
        "FIGREF92": {
            "text": "Figure S4 A",
            "latex": null,
            "type": "figure"
        },
        "FIGREF94": {
            "text": "of experimental approach. Stated are the sample numbers from each cohort (COVID-19, HAP and HCs) before and after quality control, for every cytometry panel and in case of COVID-19 for every severity grade per TP. B: UMAPs showing the total CD45 pos compartment of combined samples. Individual plots are overlaid with the expression of included markers. 1000 cells were subsetted from every sample from each cohort. C: Heatmap depicting median expression of various markers in FlowSOM-derived main population clusters. D: Box plots depicting median frequencies and 25th and 75th percentile of FlowSOMgenerated immune cell cluster. Significant p values are depicted using an asterisk (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001, Mann-Whitney test, BH correction). E: Principle Component (PC) analysis of the total immune compartment based on the markers used in the surface panel and stratified by the sample origin.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF95": {
            "text": ": Principle Component (PC) analysis of the total immune compartment based on the markers used in the surface panel and stratified by sex. G: Principle Component (PC) analysis of the total immune compartment based on the markers used in the surface panel and stratified by age.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF96": {
            "text": "referring to Figure 2) A: UMAPs showing the total T cell compartment of combined samples. Individual plots are overlaid with the expression of included markers. 1000 cells were subsetted from every sample from each cohort. B: Heatmap depicting median expression of relevant markers in FlowSOM-derived T cell clusters. C: Median expression of PD-1 within indicated FlowSOM-generated T cell subsets of HCs shown in grey and of mild and severe COVID-19 patients across TPs 1-5 shown in red. D: Box plots depicting median frequency and 25th and 75th percentile of CTLA-4 positive CD4 + EM T cells of HCs, COVID-19m and COVID-19s patients. Data from all TPs were plots depicting frequency and 25th and 75th percentile of GM-CSF positive T cell subsets of HCs, COVID-19m and COVID-19s patients. Data from all TPs were pooled. Significant p values are depicted using an asterisk (* = p < 0.05, ** = p < 0.01 and *** = p < 0.001, Mann-Whitney test, BH correction). L: Median frequency of GM-CSF positive cells within indicated FlowSOM-generated T cell subsets of HCs shown in grey and of COVID-19m and COVID-19s patients across TPs 1-5 shown in red. M: Expression levels of CSF2 (GM-CSF) in indicated cell subsets of COVID-19 patients measured by scRNA-seq. N: Expression levels of indicated genes in CSF2 (GM-CSF) high and low CD4 + T cells of COVID-19 patients measured by scRNA-seq.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF97": {
            "text": "referring to Figure 3) A: UMAPs showing the total NK cell compartment of combined samples. Individual plots are overlaid with the expression of included markers. 1000 cells were subsetted from every sample from each cohort. B: UMAPs showing the total monocyte and DC compartment of combined samples. Individual plots are overlaid with the expression of included markers. 1000 cells were subsetted from every sample from each cohort. C: Box plots depicting median expression and 25th and 75th percentile of CD95 in indicated FlowSOM-generated DC subsets. Data from TP 1 and 2 were pooled. Median expression of CD95 within indicated T cell subsets of HCs shown in grey and of COVID-19m and COVID-19s patients across TPs 1-5 shown in red. plots depicting median expression and 25th and 75th percentile of CCR2 in FlowSOMgenerated monocyte subsets, combined for TP 1 and 2 (left panel) or displayed for every individual TP (right panel). Significant p values are depicted using an asterisk (* = p < 0.05, ** = p < 0.01 and **** = p < 0.0001, Mann-Whitney test, BH correction). G: Correlation between IFN\u03b1 serum protein level against the severity grade of COVID-19 patients. All TPs were pooled.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF98": {
            "text": "referring to Figure 4) A: Box plots depicting median expression and 25th and 75th percentile of HLA-DR (left panel) and CD86 (right panel) in indicated FlowSOM-generated monocyte or DC subsets. Data from TP 1 and 2 were pooled. Significant p values are depicted using an asterisk (* = p < 0.05, ** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001, Mann-Whitney test, BH correction). B: Median expression of CD86 within cDC2s (left panel) or intermediate monocytes (right panel). Boxplot of HCs shown in grey, HAP in blue and COVID-19m and COVID-19s patients shown in red across TPs 1-5. C: Correlation between median expression of HLA-DR in classical monocytes (TP 1 and 2 pooled) against the severity grade of COVID-19 patients. D: Correlation between median expression of CD86 in classical monocytes (TP 1 and 2 pooled) against the severity grade of COVID-19 patients.",
            "latex": null,
            "type": "figure"
        },
        "FIGREF99": {
            "text": "referring to Figure 5) A: Box plots depicting median frequency and 25th and 75th percentile of FlowSOM-generated T cell subsets. Significant p values are depicted using an asterisk (* = p < 0.05 and ** = p < 0.01, Mann-Whitney test, BH correction). B: Median expression of PD-1 within FlowSOM-generated CD4 + EM T cell subset. Boxplot of HCs shown in grey, HAP patients in blue and COVID-19m and COVID-19s patients across TPs 1-5 shown in red. C: Expression levels of indicated genes in PDCD1 (PD-1) high and low CD4 + T cells of COVID-19 patients measured by scRNA-seq. expression of CD161 within FlowSOM-generated CD4 -CD8 -(TCRgd enriched) T cell subset. Boxplot of HCs shown in grey, HAP patients in blue and COVID-19m and COVID-19s patients across TPs 1-5 shown in red. F: Median expression of CD161 within indicated FlowSOM-generated NK cell subsets. Boxplot of HCs shown in grey, HAP patients in blue and COVID-19m and COVID-19s patients across TPs 1-5 shown in red. G: Median expression of CD95 within indicated FlowSOM-generated NK cell subsets. Boxplot of HCs shown in grey, HAP patients in blue and COVID-19m and COVID-19s patients across TPs 1-5 shown in red.H: Box plots depicting median frequency and 25th and 75th percentile of FlowSOM-generated NK cell subsets. Significant p values are depicted using an asterisk (* = p < 0.05, ** = p < 0.01, *** = p < 0.001 and **** = p < 0.0001, Mann-Whitney test, BH correction).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF100": {
            "text": "referring to Figure 6) A: Bar graph demonstrates the predicted number of binding peptides from SARS-CoV-2 per indicated HLA class I allele which occurred in our study population. B: Bar graphs show the number of predicted tightly binding peptides from SARS-CoV-2 per indicated HLA class I gene (summarized from both alleles) calculated for each individual study patient. The resulting values are further called HLA-A, HLA-B or HLA-C score 50. C: Correlation between indicated blood values (TP 1 only) as well as age and BMI against the severity grade of COVID-19 patients. D: Box plots depicting median counts and 25th and 75th percentile of erythrocytes, platelets, leukocytes, lymphocytes, monocytes and granulocytes at TP 1. Significant p values are depicted using an asterisk (* = p < 0.05, *** = p < 0.001 and **** = p < 0.0001, Mann-Whitney test, BH correction).",
            "latex": null,
            "type": "figure"
        },
        "FIGREF101": {
            "text": "referring to Figure 7) A: Box plots depicting the median frequency and 25th and 75th percentile of ACE2 positive cells in indicated FlowSOM-generated T cell subsets. All TPs have been pooled. Significant p values are depicted using an asterisk (* = p < 0.05, *** = p < 0.001 and **** = p < 0.0001, Mann-Whitney test, BH correction). heatmap depicting the median expression of various markers in FlowSOMderived clusters of PMA and ionomycin stimulated (5h) samples. D: Representative flow cytometry plot showing ACE2 and isotype staining (x axis) against FoxP3 staining (y axis) within the CD4 + T cell compartment of PMA and ionomycin stimulated (5h) HC samples. E: Box plots depicting the median frequency and 25th and 75th percentile of cytokine positive cells in FlowSOM-generated CD4 + ACE2 enriched cluster after PMA and ionomycin stimulation (5h). All TPs have been pooled.",
            "latex": null,
            "type": "figure"
        },
        "TABREF0": {
            "text": "indicated time points post-admission to the hospital(Table S1C). COVID-19 patients were graded according to the maximum severity of disease during the study based on the WHO",
            "latex": null,
            "type": "table"
        },
        "TABREF1": {
            "text": "at 4\u00b0C.",
            "latex": null,
            "type": "table"
        },
        "TABREF3": {
            "text": "Int. Monocytes",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": [
        {
            "text": "We thank the patients and blood donors who contributed to this study, and the hospitals at 492 Nantes, Toulouse and T\u00fcbingen for sample and data collection. Regarding specifically the **** ****",
            "cite_spans": [],
            "ref_spans": [],
            "section": "491"
        }
    ]
}